Peregrine Pharmaceuticals Company Profile (NASDAQ:PPHM)

About Peregrine Pharmaceuticals (NASDAQ:PPHM)

Peregrine Pharmaceuticals logoPeregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company's subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PPHM
  • CUSIP: N/A
  • Web: www.peregrineinc.com
Capitalization:
  • Market Cap: $183.99 million
  • Outstanding Shares: 45,096,000
Average Prices:
  • 50 Day Moving Avg: $3.34
  • 200 Day Moving Avg: $3.89
  • 52 Week Range: $1.96 - $5.78
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: Infinity
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $79.1 million
  • Price / Sales: 2.33
  • Book Value: $1.24 per share
  • Price / Book: 3.29
Profitability:
  • EBITDA: ($17,420,000.00)
  • Net Margins: -23.15%
  • Return on Equity: -38.19%
  • Return on Assets: -16.66%
Debt:
  • Current Ratio: 1.67%
  • Quick Ratio: 1.10%
Misc:
  • Average Volume: 238,466 shs.
  • Beta: 2.56
  • Short Ratio: 1.95
 

Frequently Asked Questions for Peregrine Pharmaceuticals (NASDAQ:PPHM)

What is Peregrine Pharmaceuticals' stock symbol?

Peregrine Pharmaceuticals trades on the NASDAQ under the ticker symbol "PPHM."

When did Peregrine Pharmaceuticals' stock split? How did Peregrine Pharmaceuticals' stock split work?

Peregrine Pharmaceuticals shares reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Peregrine Pharmaceuticals stock prior to the reverse split would have 14 shares after the split.

How were Peregrine Pharmaceuticals' earnings last quarter?

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) announced its quarterly earnings data on Monday, September, 11th. The company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.06. The firm earned $27.08 million during the quarter, compared to analysts' expectations of $15.22 million. Peregrine Pharmaceuticals had a negative return on equity of 38.19% and a negative net margin of 23.15%. View Peregrine Pharmaceuticals' Earnings History.

When will Peregrine Pharmaceuticals make its next earnings announcement?

Peregrine Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, December, 11th 2017. View Earnings Estimates for Peregrine Pharmaceuticals.

Where is Peregrine Pharmaceuticals' stock going? Where will Peregrine Pharmaceuticals' stock price be in 2017?

1 brokerages have issued 12-month target prices for Peregrine Pharmaceuticals' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Peregrine Pharmaceuticals' share price to reach $10.00 in the next twelve months. View Analyst Ratings for Peregrine Pharmaceuticals.

Who are some of Peregrine Pharmaceuticals' key competitors?

Who are Peregrine Pharmaceuticals' key executives?

Peregrine Pharmaceuticals' management team includes the folowing people:

  • Carlton M. Johnson Jr., Independent Chairman of the Board
  • Steven W. King, President, Chief Executive Officer, Director
  • Paul J. Lytle, Chief Financial Officer
  • Mark R. Ziebell, Vice President, General Counsel, Corporate Secretary
  • Shelley P.M. Fussey Ph.D., Vice President - Intellectual Property
  • Joseph S. Shan, Vice President - Clinical & Regulatory Affairs
  • David H. Pohl, Independent Director
  • Eric S. Swartz, Independent Director

Who owns Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include STAFFORD JOHN S III (7.30%), STAFFORD JOHN S III (7.30%) and Eqis Capital Management Inc. (0.32%). View Institutional Ownership Trends for Peregrine Pharmaceuticals.

Who sold Peregrine Pharmaceuticals stock? Who is selling Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for Peregrine Pharmaceuticals.

How do I buy Peregrine Pharmaceuticals stock?

Shares of Peregrine Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Peregrine Pharmaceuticals' stock price today?

One share of Peregrine Pharmaceuticals stock can currently be purchased for approximately $4.08.


MarketBeat Community Rating for Peregrine Pharmaceuticals (NASDAQ PPHM)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about Peregrine Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Peregrine Pharmaceuticals (NASDAQ:PPHM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00 (145.10% upside)
Consensus Price Target History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Price Target History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Analysts' Ratings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/29/2017Noble FinancialInitiated CoverageBuy -> Buy$10.00LowView Rating Details
9/13/2016Roth CapitalReiterated RatingNeutral$3.50N/AView Rating Details
9/12/2016FBR & CoReiterated RatingOutperform$7.00N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Earnings by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Earnings History by Quarter for Peregrine Pharmaceuticals (NASDAQ PPHM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/11/2017        
9/11/2017Q1 2018($0.12)($0.06)$15.22 million$27.08 millionViewN/AView Earnings Details
7/14/2017Q4 2017($0.07)($0.16)$22.57 million$17.90 millionViewN/AView Earnings Details
3/13/2017Q3 2017($0.21)($0.28)$14.02 million$10.75 millionViewN/AView Earnings Details
12/12/2016Q217($0.21)($0.14)$587.49 million$23.40 millionViewN/AView Earnings Details
9/8/2016Q1($0.28)($0.35)$13.08 million$5.61 millionViewN/AView Earnings Details
7/14/2016Q416($0.21)($0.35)$15.80 million$18.78 millionViewListenView Earnings Details
3/9/2016Q316($0.49)($0.56)$7.96 million$6.71 millionViewListenView Earnings Details
12/10/2015Q216($0.63)($0.49)$7.35 million$9.52 millionViewListenView Earnings Details
9/9/2015Q116($0.56)($0.56)$7.96 million$9.67 millionViewN/AView Earnings Details
7/14/2015Q315($0.56)($0.49)$6.42 million$9.31 millionViewListenView Earnings Details
3/12/2015Q215($0.56)($0.56)$4.20 million$5.68 millionViewN/AView Earnings Details
12/10/2014Q115($0.49)($0.49)$5.82 million$6.30 millionViewN/AView Earnings Details
9/9/2014Q1($0.42)($0.56)$5.76 million$5.50 millionViewListenView Earnings Details
7/14/2014Q414($0.49)($0.42)$4.75 million$6.47 millionViewN/AView Earnings Details
3/7/2014Q314($0.42)($0.42)$5.09 million$3.90 millionViewN/AView Earnings Details
12/10/2013Q2($0.35)($0.35)$5.74 million$7.35 millionViewListenView Earnings Details
9/9/2013Q1 2014($0.35)($0.35)$4.75 million$4.69 millionViewN/AView Earnings Details
7/11/2013Q4 2013($0.42)($0.42)$3.57 million$4.25 millionViewN/AView Earnings Details
3/12/2013Q3 2013($0.49)($0.28)$3.90 million$7.04 millionViewN/AView Earnings Details
12/10/2012-0.08($0.63)($0.56)$4.03 million$4.03 millionViewN/AView Earnings Details
9/10/2012Q113($0.77)($0.49)$3.97 million$4.25 millionViewN/AView Earnings Details
7/16/2012($0.91)($0.70)ViewN/AView Earnings Details
3/9/2012($0.91)($0.91)ViewN/AView Earnings Details
12/12/2011($0.91)($1.12)ViewN/AView Earnings Details
9/9/2011($0.98)($0.77)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Peregrine Pharmaceuticals (NASDAQ:PPHM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.05)($0.03)($0.04)
Q2 20171($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Latest Headlines for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Source:
Loading headlines, please wait.

Social

Chart

Peregrine Pharmaceuticals (PPHM) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.